- Home
- DFTX vs INVA Comparison
DFTX vs INVA Comparison
Compare DFTX & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DFTX | INVA |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | DFTX | INVA |
|---|---|---|
| Price | $17.99 | $22.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $40.25 | $36.50 |
| AVG Volume (30 Days) | ★ 1.3M | 789.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $7.22 |
| Revenue Next Year | N/A | $8.03 |
| P/E Ratio | ★ N/A | $6.94 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $14.62 | $16.52 |
| 52 Week High | $18.70 | $25.15 |
Technical Indicators
Market Signals| Indicator | DFTX | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 51.50 |
| Support Level | $16.19 | $20.24 |
| Resistance Level | $18.09 | $22.38 |
| Average True Range (ATR) | 1.02 | 0.86 |
| MACD | 0.07 | -0.14 |
| Stochastic Oscillator | 95.57 | 22.67 |
Price Performance
Historical ComparisonAbout DFTX Definium Therapeutics Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.